Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.46 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.43 |
| ▸ | GRB2 | P62993 | 1/20 | 0.43 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 2/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29364214 | 1.00 | KEAP1 (0.46) | KEAP1NTSR1OPRD1GRB2NTSR2 | |
| SCHEMBL30631705 | 0.90 | CD4 (0.46) | KEAP1OPRD1 | |
| SCHEMBL29457591 | 0.89 | F2R (0.48) | NTSR1GRB2ITGB3ITGA2BF2 | |
| SCHEMBL29364295 | 0.89 | BDKRB2 (0.48) | NTSR1GRB2ITGB3ITGA2BF2 | |
| SCHEMBL30868635 | 0.88 | KEAP1 (0.45) | KEAP1 | |
| SCHEMBL29905998 | 0.88 | KEAP1 (0.45) | KEAP1 | |
| SCHEMBL30868651 | 0.86 | KEAP1 (0.44) | KEAP1 | |
| SCHEMBL29582550 | 0.84 | BDKRB2 (0.48) | NTSR1F2 | |
| SCHEMBL14028315 | 0.84 | RAMP3 (0.46) | KEAP1 | |
| SCHEMBL30868640 | 0.84 | NMUR2 (0.44) | KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014283-A1 | ULTRASOUND-SENSITIVE PEPTIDE PARTICLES FOR SPATIALLY RESOLVED MOLECULE DELIVERY AND METHODS OF USING THE SAME | PENN STATE RES FOUND (US) | 2026-01-15 | — | — | US | claimed |
| WO-2025090926-A1 | ULTRASOUND-SENSITIVE PEPTIDE PARTICLES WITH SURFACE-BOUND GENE EDITING TOOLS FOR SPATIALLY RESOLVED MOLECULE DELIVERY | THE PENN STATE RESEARCH FOUNDATION (US) | 2025-05-01 | — | — | WO | claimed |
| US-20240358640-A1 | ULTRASOUND-SENSITIVE PEPTIDE PARTICLES FOR SPATIALLY RESOLVED MOLECULE DELIVERY | THE PENN STATE RESEARCH FOUNDATION | 2024-10-31 | — | — | US | claimed |
| US-12064514-B2 | Ultrasound-sensitive peptide particles for spatially resolved molecule delivery | THE PENN STATE RESEARCH FOUNDATION (US) | 2024-08-20 | — | — | US | claimed |
| US-20240238383-A1 | ANTI-OXIDANT CONTAINING PARTICLES AND METHODS OF USE | UNIV OF LOWA RESEARCH FOUNDATION (US) | 2024-07-18 | — | — | US | claimed |
| US-20240109979-A1 | CELL ATTACHMENT MATERIALS, DEVICES AND USES THEREOF | FACELLITATE GMBH (DE) | 2024-04-04 | — | — | US | claimed |
| EP-4340894-A1 | ANTI-OXIDANT CONTAINING PARTICLES AND METHODS OF USE | University Of Iowa Research Foundation (US) | 2024-03-27 | — | — | EP | claimed |
| EP-4301788-A1 | CELL ATTACHMENT MATERIALS, DEVICES AND USES THEREOF | FaCellitate GmbH (DE) | 2024-01-10 | — | — | EP | claimed |
| US-11718687-B2 | Biomoletron for regulation stem cell differentiation | SOGANGN UNIVERSITY RESEARCH FOUNDATION (KR) | 2023-08-08 | — | — | US | claimed |
| WO-2022246280-A1 | ANTI-OXIDANT CONTAINING PARTICLES AND METHODS OF USE | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2022-11-24 | — | — | WO | claimed |
| WO-2022184899-A1 | CELL ATTACHMENT MATERIALS, DEVICES AND USES THEREOF | FACELLITATE GMBH (DE) | 2022-09-09 | — | — | WO | claimed |
| EP-4053163-A1 | CELL ATTACHMENT MATERIALS, DEVICES AND USES THEREOF | FaCellitate GmbH (DE) | 2022-09-07 | — | — | EP | claimed |
| US-20260014283-A1 | ULTRASOUND-SENSITIVE PEPTIDE PARTICLES FOR SPATIALLY RESOLVED MOLECULE DELIVERY AND METHODS OF USING THE SAME | PENN STATE RES FOUND (US) | 2026-01-15 | — | — | US | disclosed |
| EP-3962491-B1 | INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES | UNIV SANTIAGO COMPOSTELA (ES) | 2025-08-06 | — | — | EP | disclosed |
| US-12377191-B2 | Chondroinductive peptides and compositions and methods of use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250215411-A1 | FUSION PROTEINS AND USES THEREOF | OSPEDALE SAN RAFFAELE SRL (IT) | 2025-07-03 | — | — | US | disclosed |
| EP-4053163-A1 | CELL ATTACHMENT MATERIALS, DEVICES AND USES THEREOF | FaCellitate GmbH (DE) | 2022-09-07 | — | — | EP | disclosed |
| US-20220177603-A1 | INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2022-06-09 | — | — | US | disclosed |
| WO-2022026906-A9 | LYSOSOMAL TARGETING MOLECULES COMPRISING KNOTTIN PEPTIDES AND RELATED COMPOSITIONS AND METHODS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3962491-A1 | INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES | Universidade De Santiago De Compostela (ES) | 2022-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014283-A1 | ULTRASOUND-SENSITIVE PEPTIDE PARTICLES FOR SPATIALLY RESOLVED MOLECULE DELIVERY AND METHODS OF USING THE SAME | HDGFL3, HDGF, HM13 | KEAP1 3111/4885NTSR1 1883/4885OPRD1 2392/4885 |
| US-20220177603-A1 | INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES | KRAS, NRAS, TP53 | KEAP1 186/4885NTSR1 3869/4885OPRD1 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.